Fluconazole pharmacokinetics and safety in premature infants.

Journal Article (Journal Article;Review)

Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating its pharmacokinetics (PK) and safety have been performed in this vulnerable population. We review five phase I studies examining the PK of fluconazole in premature infants, which demonstrate markedly differing kinetics compared to adults. Based on these data, a treatment dose of 12 mg/kg/day, with the potential need of a loading dose of 25 mg/kg to achieve rapid steady state concentrations, achieves surrogate pharmacodynamic targets. Additionally, fluconazole appears to be safe to use in this population, with only minimal reversible hepatobiliary effects.

Full Text

Duke Authors

Cited Authors

  • Turner, K; Manzoni, P; Benjamin, DK; Cohen-Wolkowiez, M; Smith, PB; Laughon, MM

Published Date

  • 2012

Published In

Volume / Issue

  • 19 / 27

Start / End Page

  • 4617 - 4620

PubMed ID

  • 22876898

Pubmed Central ID

  • PMC3522083

Electronic International Standard Serial Number (EISSN)

  • 1875-533X

Digital Object Identifier (DOI)

  • 10.2174/092986712803306367


  • eng

Conference Location

  • United Arab Emirates